Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNX-1500 in Kidney Transplant Recipients
NCT07204080Phase 2Not yet recruiting
- Start
- Nov 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TNX-1500 in kidney transplant rejection. Primary endpoints: Number of Adverse Events at 12 months and Number of Serious Adverse Events at 12 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
TNX-1500
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT07204080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07204080.